Pavinetant
| CAS No. | 941690-55-7 | Cat. No. | BCP48976 |
| Name | Pavinetant | ||
| Synonyms | AZD-2624; AZD2624; AZD 2624; MLE-4901; MLE4901; MLE 4901; AZD-4901; AZD 4901; AZD4901; AZ-12472520; AZ 12472520; AZ12472520; | ||
| Formula | C26H25N3O3S | M. Wt | 459.56 |
| Description | Pavinetant is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. As of 2017, the drug is in phase II clinical trials for hot flashes and PCOS. | ||
| Pathways | Neuro Signaling Pathway GPCR/G Protein | ||
| Targets | NK Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.